NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
about
The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promiseMolecular and Cellular Mechanisms of Cardiovascular Disorders in DiabetesThioredoxin-Interacting Protein Mediates Apoptosis in Early Brain Injury after Subarachnoid HaemorrhageThioredoxin-interacting protein links endoplasmic reticulum stress to inflammatory brain injury and apoptosis after subarachnoid haemorrhage.Contribution of redox-dependent activation of endothelial Nlrp3 inflammasomes to hyperglycemia-induced endothelial dysfunctionMuscle ring finger-3 protects against diabetic cardiomyopathy induced by a high fat diet.Protection of SAL B with H9C2 cells.Loss of Nlrp3 Does Not Protect Mice from Western Diet-Induced Adipose Tissue Inflammation and Glucose Intolerance.Prohibitin overexpression improves myocardial function in diabetic cardiomyopathy.Glutamine Modulates Macrophage LipotoxicityNebivolol Ameliorates Cardiac NLRP3 Inflammasome Activation in a Juvenile-Adolescent Animal Model of Diet-Induced Obesity.TRPM2 regulates TXNIP-mediated NLRP3 inflammasome activation via interaction with p47 phox under high glucose in human monocytic cells.PEDF Inhibits the Activation of NLRP3 Inflammasome in Hypoxia Cardiomyocytes through PEDF Receptor/Phospholipase A2.Diabetic Cardiomyopathy: An Immunometabolic Perspective.LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy.SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.NLRP3 at the interface of metabolism and inflammation.T2DiACoD: A Gene Atlas of Type 2 Diabetes Mellitus Associated Complex Disorders.Thioredoxin-Interacting Protein Mediates NLRP3 Inflammasome Activation Involved in the Susceptibility to Ischemic Acute Kidney Injury in Diabetes.Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance.Terminal complexes of the complement system: new structural insights and their relevance to function.NLRP3 inflammasome: Its regulation and involvement in atherosclerosis.An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy.Inflammation and metabolic cardiomyopathy.IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus.NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy.High Glucose and Lipopolysaccharide Prime NLRP3 Inflammasome via ROS/TXNIP Pathway in Mesangial Cells.NLRP3 Inflammasome Activation-Mediated Pyroptosis Aggravates Myocardial Ischemia/Reperfusion Injury in Diabetic Rats.NF-κβ: A Potential Target in the Management of Vascular Complications of Diabetes.NLRP3-inflammasome inhibition prevents high fat and high sugar diets-induced heart damage through autophagy induction.Acute fasting inhibits central caspase-1 activity reducing anxiety-like behavior and increasing novel object and object location recognition.The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC.Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases.Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease.NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension.H3 relaxin inhibits the collagen synthesis via ROS- and P2X7R-mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose.The regulation of NLRP3 inflammasome expression during the development of cardiac contractile dysfunction in chronic kidney disease.MCMV triggers ROS/NLRP3-associated inflammasome activation in the inner ear of mice and cultured spiral ganglion neurons, contributing to sensorineural hearing loss.Pancreatic Beta Cell Death: Novel Potential Mechanisms in Diabetes Therapy.
P2860
Q26829731-B326338C-61D4-4D20-927A-E67CC7519A46Q28395675-9FBC15A4-2FEB-4FDE-979A-15ED230C1624Q33624873-CEBB9E52-FB2A-4E79-A842-1330F6ADF9DAQ33660621-33014744-CAD3-4EBA-8EDA-4C4C4621029AQ33908252-C8C54E44-7492-49C4-BAF9-0CE7394E0CB1Q35716907-3BFF449B-0D49-40C1-AE5A-B73CF90CE613Q35878597-38C7C627-4AA5-480D-A7C7-B197B78A8BE4Q36119524-F15230AF-85A9-4C4D-B178-C2B175586A17Q36729347-86EF473D-8875-4135-B8B9-BE13828BFC2CQ36846304-2BA9E661-38A0-4EDB-B7DE-229C50ECBF6CQ37298681-D7E82742-D9BB-44C1-BDE7-8AEF3FED99BFQ37330560-12DA2CB5-F64A-4866-801C-13718AA87D8DQ37534751-584224AF-9BD3-4DF1-B820-B6280D629737Q37741735-610237E7-89DD-4773-9189-B1E626C4F770Q37745110-3862578A-E8BD-4F97-AA34-910A7BF25DDBQ38288267-7FBC111A-98A4-4DF4-9B6D-B0BC696380C3Q38423371-BA967108-7843-40A2-8405-B81A3475A3D8Q38430526-EB921963-51A0-44DE-BAC9-216EC007649CQ38729962-CD14B33A-393E-4994-91C6-4E687FBB1D24Q38947693-E95CDD5D-0338-4F44-AD40-987AAE687CD9Q38991062-0B43E845-A17F-41A1-ABEF-21326A4E9DBCQ39202038-D8EB3F79-8BB5-4EFE-9FD0-3B2C9DF84DE2Q39232014-19A8A906-812F-4862-BB9A-55AEF9030A7BQ39232024-FD5D4B30-BE60-4894-B1B9-D3EF68DB2104Q39403443-541AC504-7FBC-4D86-9060-A70A6CBE562CQ41108795-77B69A46-4395-47ED-A3C8-77B561454ADFQ41856193-132CE97E-34F7-4AA6-853D-8D6CF6D55E57Q43372985-DB0A6F7B-AC1F-4F95-928B-52148BA9168EQ47094741-86ADE876-05E5-492E-8895-3C04D8C7A544Q47102694-BBCFA08C-60DA-49AC-973C-2C139C3D92B0Q47320532-AAAE839A-CA61-4749-B1EE-2F6EB6610758Q47553695-C7BBEFDB-7250-41B1-8F3A-372159885057Q47682969-528F8881-2BA4-48E0-98BB-4BFB12275E1FQ47739163-95A12A49-DB27-4CCF-8E22-462E08CBE7EFQ47807072-E5368545-7896-4140-99A9-9A0F7809B31AQ48239109-0ABBDD03-CE49-4205-A1C0-B63714FA02F0Q48285954-01454F88-29B1-4E7C-81CF-488C87DD79CEQ49678863-7B3BDB3E-4DF4-42E0-A616-E1CFB3D6CA00Q51735655-875507B7-2BDC-4898-A660-2AA9F0C15D26Q52316229-B6BB9E3B-9ED6-479B-8D67-59DC794AE1D3
P2860
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
@ast
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
@en
type
label
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
@ast
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
@en
prefLabel
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
@ast
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
@en
P2093
P2860
P1433
P1476
NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model.
@en
P2093
Beibei Luo
Cheng Zhang
Fengshuang An
Mingxiang Zhang
Wenke Wang
Xiangjuan Liu
Yanfei Xia
P2860
P304
P356
10.1371/JOURNAL.PONE.0104771
P407
P577
2014-08-19T00:00:00Z